Skipping Hormone Therapy in Low-Risk Early Breast Cancer

The goal of this clinical trial is to determine whether a selected population of women with early-stage, low-risk breast cancer can avoid hormone therapy without increasing their risk of relapse. It will also evaluate the prognosis of these participants compared to participants who received standard treatment with hormone therapy in another study, estimate the risk of specific recurrence, cardiovascular and bone health, and participants' quality of life. All participants will have undergone surgery and possibly radiation therapy, but unlike standard care, they will not receive hormone therapy

Trial Details

NCT ID
NCT07661927
Phase
PHASE2
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Ductal Carcinoma In Situ (DCIS) Breast Cancer
Interventions
  • Removing Endocrine Therapy
Locations (sample)
  • Angers, France|47.47156,-0.55202
  • Avignon, France|43.94834,4.80892
  • Bayeux, France|49.27732,-0.7039
  • Bayonne, France|43.49316,-1.473
  • Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

  • Postmenopausal (underwent bilateral oophorectomy or non-chemo induced amenorrhea for 12 or more months) female participant ≥60 years of age.
  • New diagnosis of invasive carcinoma of the breast (ductal, tubular or mucinous) with primary tumor ≤1 cm on microscopic exam with no evidence of no…
  • Contralateral breast described as BI-RADS (Breast Imaging-Reporting And Data System) 1 or 2 in diagnostic imaging.
  • Negative axillary node involvement by sentinel node biopsy or axillary node dissection (pN0) or Clinically negative axillary node involvement (cN0)…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ductal Carcinoma In Situ (DCIS) Breast Cancer Trials on Trialify →